New chemotherapy-enhancing strategies are needed for better cancer therapy. Previous studies suggest that exogenous cell-permeable C6 ceramide may be a useful adjunct to the anti-tumor effects of chemotherapeutic agents (such as Taxol) against multiple cancers. Here we demonstrate that exogenous cell-permeable C6 ceramide largely sensitizes multiple progressive cancer cell lines to Doxorubicin-induced cell death and apoptosis. We found for the first time that Doxorubicin induces AMP-activated protein kinase (AMPK) activation in a reactive oxygen species-dependent manner. Activation of AMPK contributes to Doxorubicin-induced cancer cell death and apoptosis. Inhibition of AMPK by small interfering RNA knockdown or a pharmacological inhibitor reduces Doxorubicin-induced cancer cell apoptosis, whereas AMPK activator AICAR enhances it. Importantly, we found that C6 ceramide largely enhances Doxorubicin-induced activation of AMPK, which leads to mTOR complex 1 inhibition and chemo-sensitization. Our data suggest that the combination of C6 ceramide with traditional chemotherapy drugs such as Doxorubicin may have the potential to be used as a new therapeutic intervention against multiple cancers.
Introduction
Membrane sphingolipids are shown to be biologically active and have numerous regulatory effects on cell function, including growth and differentiation. Besides as structural elements, ceramides can also act as a signaling molecule. Previous studies have shown very interesting relationship between ceramides and apoptosis in tumor cells and the processes that would enhance intracellular ceramide accumulation would provide favorable proapoptotic outcomes in cancer chemotherapy (Bose et al., 1995; Kolesnick and Kronke, 1998) . Cell-permeable ceramides (C 2 or C 6 ceramide N-hexanoyl-D-sphingosine) have shown activity against a variety of cancer cell lines (Auzenne et al., 1998; Mehta et al., 2000) (reviewed in (Kolesnick and Kronke, 1998; Radin, 2003) ). Previous studies also indicate the potential effects of cell-permeable ceramides (C6 ceramide) to enhance the pro-cell death of known chemotherapeutic agents such as Taxol (Mehta et al., 2000; Qiu et al., 2006) . These limited studies suggest that C6 ceramide could be useful as an adjunct to conventional chemotherapeutics. However, whether cell-permeable C6 ceramide could sensitize cancer cells to Doxorubicin-induced cell death or apoptosis is also not fully studied; also, the molecular mechanisms involved in this synergistic effect are also largely elusive.
Doxorubicin is one of the most commonly used anticancer drugs, but its application has been limited by the presence of cellular resistance (Hortobagyi, 1997) and acute cardiotoxicity (Zhu et al., 2009) , partly because of the lack of information regarding the detailed cellular mechanisms by which Doxorubicin induce cell death. Recent studies on human cancer have established mTOR complex 1 (mTORC1) as a major regulator of cell survival to protect the cells from various therapeutic agents, including Doxorubicin; inhibition of mTORC1 sensitizes cancer cells to Doxorubicin-induced antitumor effect (Grunwald et al., 2002; Piguet et al., 2008) . Interestingly, a recent study indicates that Doxorubicin treatment induces acute inhibition of mTORC1, which is the major contributor to acute Doxorubicin cardiotoxicity and cell apoptosis. However, the cellular mechanism involved in mTORC1 inhibition by Doxorubicin is not fully studied, though it is indicated that reactive oxygen species (ROS) production and p53 activation may be involved (Zhu et al., 2009) . Among the signal molecules that negatively regulate mTORC1 activation, AMP-activated protein kinase (AMPK) is the major one (Carling, 2004; Steinberg and Kemp, 2009) .
AMPK is a heterotrimeric serine-threonine kinase that senses depletion of intracellular energy and responds by stimulating catabolic pathways that generate ATP (Carling, 2004; Kahn et al., 2005) . One mechanism for sensing cellular energy levels involves allosteric activation of the kinase activity of AMPK, under conditions in which cellular energy demands are increased or when fuel availability is decreased, intracellular ATP is reduced and AMP levels rise. AMP then allosterically activates AMPK. In addition to allosteric activation, AMPK activity can also be regulated by a mechanism involving covalent modification through the addition of a phosphate group by other molecules such as LKB1 and CaMK or calmodulin-dependent protein kinase (Steinberg and Kemp, 2009) . Until now, lots of stimuli (Yamauchi et al., 2008; Yoon et al., 2008) have been found that can induce AMPK activation.
AMPK has three subunits, including a, b and g subunits. Activation of AMPK requires phosphorylation of Thr 172 in the activation loop of a subunit by upstream AMPK kinase (Kahn et al., 2005; Ruderman et al., 2006; Arad et al., 2007; Towler and Hardie, 2007) . AMPK activation also triggers a phosphorylation cascade that regulates the activity of various downstream targets, including transcription factors, enzymes and other regulatory proteins, such as mTOR pathways (Inoki et al., 2003) , p53 (Jones et al., 2005) and p38 (Yoon et al., 2006) . The key function of AMPK is to regulate the energy balance within the cell; however, recent studies also indicate that AMPK activation modulates other important cellular functions, including promoting apoptosis (Morgillo et al., 2006; Cao et al., 2008; Kim do et al., 2009; Chiang et al., 2010 ).
Here we demonstrate that exogenous C6 ceramide largely sensitizes multiple cancer cell lines to Doxorubicin-induced cell death and apoptosis. Doxorubicin induces AMPK activation in an ROS-dependent manner, which contributes to cancer cell apoptosis. Importantly, we found that C6 ceramide largely enhances Doxorubicin-induced activation of AMPK, which leads to mTORC1 inhibition and chemo-sensitization. Our data suggest that combining C6 ceramide with traditional chemotherapy drugs such as Doxorubicin may have the potential to be used s a new therapeutic intervention against multiple cancers.
Results
C6 ceramide dramatically sensitizes Doxorubicin/ Etoposide-induced cancer cell death in vitro We first test the chemo-sensitization effects of C6 ceramide on the cancer cell death induced by Doxorubicin and another topoisomerase II inhibitor, Etoposide, by simply using cell viability assay (3-[4, 5-dimethylthylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay). The MTT assay is standard colorimetric assay for measuring the activity of enzymes in mitochondria that reduce MTT to formazan, giving a purple color. The assay is, therefore, largely a measure of mitochondrial activity and an indication of cell viability. Those agents that result in cell toxicity and mitochondrial dysfunction will lead to decreased performance in the assay. Cancer cell death can be indicated as reduced cell viability. As shown in Figures 1a-d, although C6 ceramide itself alone has little effects on cancer cell death except at a very high concentration, it dramatically enhances Doxorubicininduced cancer cell death in a dose-dependent manner in both pancreatic cancer cell line L3.6 cells and breast cancer cell line MCF-7 cells. We choose C6 ceramide at the concentration of 10 mg/ml for the following experiment, as at this concentration, C6 ceramide alone has almost no effects in killing cancer cells, although it dramatically enhances cancer cell death when added with Doxorubicin (Figures 1b and d Figure S1g described above. The apoptosis rate was quantified in Figure 2b . The synergistic effects of C6 ceramide and Doxorubicin on cancer cell apoptosis were also confirmed by using Histone DNA apoptosis enzyme-linked immunosorbent assay ( Figure 2c Doxorubicin induces AMPK activation in multiple cancer cell lines in vitro As discussed above, activation of AMPK pathway serves as an important cellular mechanism in regulating cell apoptosis (Morgillo et al., 2006; Kim do et al., 2009; Chiang et al., 2010) . We next, test the possible role of this signal pathway in Doxorubicin-induced cancer cell death/apoptosis. As demonstrated in Figure 3a , Doxorubicin alone clearly triggers AMPK (Thr172 phosphorylation) activation and downstream AcetylCoA Carboxylase (Ser79) phosphorylation. As previous studies have indicated that ROS is able to induce strong AMPK activation (Morgillo et al., 2006; Zhang et al., 2007; Cao et al., 2008; Jung et al., 2008) and Doxorubicin induces production of ROS in cancer cells (Ravid et al., 1999; Nithipongvanitch et al., 2007) , we next test the involvements of ROS in Doxorubicininduced AMPK activation. As seen in Figures 3b and c , Doxorubicin induces ROS production in MCF-7 breast cancer cells, and anti-oxidants Nac and MnTBAP inhibit Doxorubicin-induced AMPK activation. .6, CaOV3 and WM-115 cells were treated with Doxorubicin (0.3 mg/ml) and cultured for15, 30, 60, 120 and 240 min. p-AMPKa (Thr 172), p-ACC(Acetyl-CoA Carboxylase) (Ser79) and AKT1/2 were detected by western blot (a). MCF-7 Cells were pre-treated with anti-oxidant N-acetyl-cysteine (NAC, 400 mM) or Mn(III)tetrakis (4-benzoic acid) porphyrin (MnTBAP, 500 mM) for 1 h, followed by Doxorubicin (0.3 mg/ml) for 1 or 2 h, ROS production were detected by FACS as described (b), p-AMPKa (Thr 172), p-ACC (Ser79) and AKT1/2 were detected by western blot (c). H 2 O 2 -induced AMPK activation in MCF-7 cells were detected by western blots (d). MCF-7 (e) and L3.6 (f) Cells were pre-treated with anti-oxidant NAC (400 mM) or MnTBAP (500 mM) for 1 h, followed by Doxorubicin (0.3 mg/ml) treatment for 48 h, cell viability was detected by MTT assay. MCF-7 (g) and L3.6 (h) were treated with different concentration of H 2 O 2 with or without C6 ceramide (10 mg/ml), cell viability was detected 48 h later by using MTT assay. (Figure 3d) . Notably, inhibition of the ROS production and AMPK activation by NAC or MnTBAP inhibits Doxorubicin-induced cell death in MCF-7 cells and L3.6 cells (Figures 3e and f) , suggesting that ROS-mediated AMPK activation might be involved in Doxorubicin-induced cancer cell death. Interestingly, C6 ceramide also enhances H 2 O 2 -induced cancer cell apoptosis in L3.6 and MCF-7 Cells (Figures  3g and h ).
AMPK activation contributes Doxorubicin-induced cancer cell apoptosis
Since published studies have demonstrated the critical role of AMPK activation in cell death or apoptosis (Okoshi et al., 2007; Cao et al., 2008) , we next examined the possible involvements of AMPK activation in Doxorubicin-induced cancer cell death. Specific small interfering RNA (siRNA) was used here to knock down AMPKa in both MCF-7 and L3.6 cells (Supplementary Figure S3) . As shown in Figures 4a-f AMPKa siRNA knockdown (Figures 4a and b) inhibits Doxorubicin- AMPK activation is involved in Doxorubicin-induced cancer cell death. L3.6 cells and MCF-7 cells with control siRNA or AMPKa siRNA were treated with Doxorubicin (0.3 mg/ml). AMPK activation were detected 2 h after Doxorubicin treatment by using western blots (a, b). Cell viability were detected 48 h after Doxorubicin treatment (c, e), and cell apoptosis were detected 36 h after Doxorubicin treatment by using histone DNA apoptosis ELISA assay (d, f). MCF-7 Cells and L3.6 cells were pre-treated with AMPK activator AICAR (500 mM) for 1 h, followed by Doxorubicin (0.3 mg/ml) for 1 or 2 h, p-AMPKa (Thr 172) and AKT1/2 were detected by western blot (g, h). Cell viability of MCF-7 and L3.6 cells with indicated treatment (Control, 10 mM of compound C/AMPKi, 500 mM of AICAR, 0.3 mg/ml of Doxorubicin, compound C plus Doxorubicin or AICAR plus Doxorubicin) for 48 h were detected by MTT assay (i, j). *Po0.05 vs Doxorubicin treated group in control siRNA transfected cells. **Po0.05 vs Doxorubicin only treatment. Data are presented as the mean ± s.d. for three independent experiments. All experiments were repeated at least three times and similar results were obtained. (Figures 4g and h ), enhances it in both MCF-7 and L3.6 cells (Figures 4i and j) . Collectively, our data suggest that the activation of AMPK contributes to Doxorubicin-induced cancer cell death and apoptosis.
C6 ceramide enhances Doxorubicin-induced AMPK activation, leading to mTORC1 inhibition and cancer cell apoptosis As we have shown that Doxorubicin alone induces AMPK activation, which contributes to cancer cell death and apoptosis and the effects of Doxorubicin on cancer cell death and apoptosis were largely enhanced by C6 ceramide, we next tested the possible role of C6 ceramide on Doxorubicin-induced AMPK activation. As shown in Figures MCF-7 and L3.6 cells were treated with C6 ceramide (10 mg/ml) alone, Doxorubicin (0.3 mg/ml) alone or C6 ceramide plus Doxorubicin for 1 and 2 h, p-AMPKa (Thr 172), p-ACC (Ser79) and AKT1/2 were detected by western blot, AMPKa(Thr 172) phosphorylation in both cells was quantified as fold change (a, b). The effects of AMPK inhibitor AMPKi (compound C, 10 mM) or AMPKa1/2 siRNA knockdown on indicated treatments (control, 0.3 mg/ml of Doxorubicin alone or with 10 mg/m of C6 ceramide) induced S6 and S6K phosphorylation (36 h after treatments) were detected by western blot (c, d). S6K phosphorylation in L3.6 cells wasquantified in e (normalized to AKT1/2). ROS production in MCF-7 cells and L3.6 cells with indicated treatments (control, C6 ceramide (10 mg/ml) alone, Doxorubicin (0.3 mg/ml) alone or C6 ceramide plus Doxorubicin for 2 h) were detected in f and g. *Po0.05 vs group with Doxorubicin treatment only at same time point. Data are presented as the mean ± s.d. for three independent experiments. # Po0.05 vs group without compound C pre-treatment (e, left). *Po0.05 vs group without AMPKa1/2 siRNA (e, right). ** Po0.05 vs group with Doxorubicin treatment (f, g).All experiments were repeated at least three times and similar results were obtained.
AMPK activation and mTORC1 inhibition by Doxorubicin C Ji et al enhances Doxorubicin-induced AMPK activation in both MCF-7 cells and L3.6 cells. As we discussed above, targeting mTORC1 inhibition enhances cancer cells' response to chemotherapy drugs including Doxorubicin, and AMPK has been well established to negatively regulate mTORC1 activation by phosphorylating activation of TSC2, an upstream negative regulator of mTORC1 (Carling, 2004; Inoki et al., 2006; Jaswal et al., 2006) . As shown in Figures 5c, d and e, Doxorubicin alone, which induces moderate activation of AMPK, partially inhibits mTORC1 activation (S6K, S6 phosphorylation), whereas adding C6 ceramide, which largely enhances AMPK activation, dramatically reduces mTORC1. Notably, the inhibition of mTORC1 by either Doxorubicin alone or in combination with C6 ceramide was largely reversed either by adding AMPK inhibitor compound C or by AMPK RNA interference, indicating that AMPK activation is responsible for Doxorubicin or Doxorubicin plus C6 ceramide-induced mTORC1 inhibition in both cells (Figures 5c-e) . Based on the above discussion that ROS production is involved in Doxorubicininduced AMPK activation, we next tested the effects of C6 ceramide on Doxorubicin-induced ROS production. As shown in Figures 5f and g, C6 ceramide enhances Doxorubicin-induced ROS production in both cells, which could explain the enhanced AMPK activation observed for the combination treatments. Interestingly enough, C6 ceramide alone seemed to have almost no effect on AMPK activation (Figures 5a and b) or ROS production (Figures 5f and g ).
C6 ceramide enhances Doxorubicin-induced Bcl2 downregulation
Among the mTOC1-regulated genes, Bcl-2 has been implicated in the resistance of tumor cells to the proapoptotic effects of Doxorubicin (Romano et al., 2004; Zhang et al., 2007) . For this reason, we investigated if mTORC1 inhibition could sensitize cancer cells to apoptosis through a decrease in the levels of this antiapoptotic protein. Western blotting analysis of cell lysates obtained after 36 h of rapamycin treatment showed the decreased Bcl2 expression in both L3.6 and MCF-7 cells (Figures 6a and d) . As expected, rapamycin enhances Doxorubicin-induced cell death and apoptosis in both MCF-7 and L3.6 cells ( Figures  6b, c, e and f) . Doxorubicin, which inhibits mTORC1 activation, also decreases Bcl2 expression after 36 h treatment. Importantly, C6 ceramide largely promotes the downregulation of Bcl2 by Doxorubicin in both types of cells (Figures 6g and i) , which might serve as a key mechanism to sensitize cancer cell to chemo-drugsinduced apoptosis. Importantly, AMPKa knockdown by specific siRNA largely reduces C6 þ Dox-induced Bcl-2 downregulation in both cells (Figures 6h and j) . Nac, the antioxidant that inhibits AMPK activation by Doxorubicin, also inhibits C6 þ Dox-induced Bcl-2 downregulation (Figure 6l ) and cell death (Figures 6m) in MCF-7 cells. Based on this information, we suggest that C6 plus Doxorubicin treatment induces stronger AMPK activation, leading to further mTORC1 inhibition, which is a response for further Bcl-2 downregulation and cell apoptosis.
Discussion
As well as the numerous metabolic targets of AMPK for which it is best known, it is becoming increasingly clear that AMPK has many other downstream effectors. Recent findings suggest that AMPK inhibits cell growth and proliferation, and also positively regulates apoptosis (Ravid et al., 1999; Morgillo et al., 2006; Nithipongvanitch et al., 2007; Okoshi et al., 2007; Cao et al., 2008; Kim do et al., 2009; Chiang et al., 2010) . These findings are not surprising, given that cell growth, DNA replication and mitosis are all major consumers of ATP, and also that the upstream regulator of AMPK, LKB1, is known to be a tumor suppressor. In this study, we discovered for the first time that Doxorubicin induces AMPK activation in multiple cancer cell lines (Figure 3) . ROS production by Doxorubicin is involved in AMPK activation (Figure 3 ). Using AMPK inhibitor (compound C), AMPKa siRNA knockdown as well as AMPK activator AICAR, we observed that AMPK activation contributes to Doxorubicin-induced cancer cell apoptosis (Figures 4 and 5) by negatively regulating mTORC1 and downregulating Bcl-2 (Figures 5 and 6) Figure 6 C6 ceramide enhances Doxorubicin induced Bcl-2 downregulation. MCF-7 and L3.6 cells were treated with Rapamycin (25 nM) for 36 h, Bcl2 expression and S6K phosphorylation were detected by western blots (a, d). MCF-7 and L3.6 cells were pretreated with Rapamycin (25 nM) for 1 h, followed by Doxorubicin (0.3 mg/ml), cancer cells viability were detected by MTT assay 48 h later (b, e), cancer cell apoptosis was detected using hoechst/calcein assay 36 h later and quantified in c and f. MCF-7 and L3.6 cells were treated with Doxorubicin (0.3 mg/ml) with or without C6 ceramide (10 mg/ml) for 36 h, Bcl2 expression were detected by western blots (g, i). L3.6 cells and MCF-7 cells with control siRNA or AMPKa1/2 siRNA were treated with Doxorubicin (0.3 mg/ml) plus C6 ceramide (10 mg/ml) for 36 h, AMPKa, Bcl-2 and loading were detected by Western blot (h, j). MCF-7 cells were pre-treated with NAC (400 mM) for 1 h, followed by H 2 O 2 (0.5 mM) or Doxorubicin (0.3 mg/ml) plus C6 ceramide (10 mg/ml) treatment, S6K phosphorylation, Bcl-2 expression and b-actin were detected 36 h later by western blot (l), cancer cells viability were detected by MTT assay 48 h later (m). (n) Possible signal pathway involved in this study: Doxorubicin induces ROS production, which serves as an upstream signal for AMPK activation. Activation of AMPK inhibits the activation of mTORC1 and down-regulates anti-apoptosis proteins such as Bcl2 as well as other mTORC1 response proteins, leading to cancer cell apoptosis. C6 ceramide enhances Doxorubicin-induced AMPK activation and mTORC1inhibition, probably by induces more ROS production, contributing to further cancer cell death and chemosensitization. Data are presented as the mean ± s.d. for three independent experiments. * Po0.05 vs group without Rapamycin pre-treatment. # Po0.05 vs group without NAC pre-treatment. All experiments were repeated at least three times and similar results were obtained.
AMPK activation and mTORC1 inhibition by Doxorubicin
C Ji et al and other possible AMPK downstream signals such as p53 (Okoshi et al., 2007) and metabolic targets, which needs further investigation. The anti-tumor synergism exhibited in vitro by addition of exogenous ceramide to Doxorubicin suggests a unique biological interaction rather than a mere addition of two cytotoxic agents. Doxorubicin increases endogenous ceramide, which then is considered to switch on pro-apoptotic pathways (Rath et al., 2009) . However, in this study C6 ceramide alone, even at a relative high dosage, has a very weak effect on cancer cell death or apoptosis (Figure 1) , which is consistent with the finding that C6 ceramide alone also has almost no effect on AMPK activation ( Figure 5 ) nor mTORC1 inhibition (data not shown). When added with Doxorubicin, C6 ceramide largely enhances AMPK activation, AMPK activation and mTORC1 inhibition by Doxorubicin C Ji et al promoting cancer cell apoptosis. These results suggest that C6 ceramide is necessary but not sufficient to induce both AMPK activation and cancer-cell apoptosis by Doxorubicin. Other signals are required to initiate AMPK activation by Doxorubicin, which needs further investigation.
In conclusion, we demonstrate for the first time that Doxorubicin induces AMPK activation in an ROSdependent manner in multiple cancer cell lines. AMPK activation contributes to Doxorubicin-induced cancer cell death and apoptosis by mTORC1 inhibition and possible other downstream targets. Exogenous cellpermeable C6 ceramide sensitizes Doxorubicin-induced cancer cell death and apoptosis in multiple tumor cancer cell lines. Importantly, C6 ceramide largely enhances Doxorubicin-induced AMPK activation, leading to mTORC1 inhibition, Bcl2 down-regulation and chemosensitization, which could be the key mechanism to explain the synergism of combination of these two drugs.
Materials and methods
Chemicals and reagents C6 ceramide was purchased from Avanti (Alabaster, AB, CN: 860506P); Doxorubicin, Taxol, Etoposide, AMPK inhibitor Compound C, AMPK activator AICAR and Rapamycin were purchased from CalbioChem (San Diego, CA, USA). Bcl-2, ERK1/2, AKT1/2, AMPKa1, AMPKa2, goat anti-rabbit IgG-HRP and goat anti-mouse IgG-HRP antibody were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). N-acetyl-cysteine (NAC), MnTBAP, H 2 O 2 and monoclonal mouse anti-b-actin were obtained from Sigma (St Louis, MO, USA). p-AMPKa (Thr 172), T-AMPKa, p-acetyl-CoA carboxylase (Ser 79), p-S6K (Thr389) and p-S6 (S235/236) antibody were purchased from Cell Signaling Technology (Beverly, MA, USA).
Cell culture
Ovarian cancer cell lines CaOV3, breast cancer cell line MCF-7, pancreatic cancer cell line L3.6 and melanoma cancer cell line WM-115 cells were maintained in a DMEM medium (Sigma), supplemented with a 8% fetal bovine serum (Invitrogen, Carlsbad, CA, USA), penicillin/streptomycin (1:100, Sigma) and 4 mM L-glutamine (Sigma), in a CO 2 incubator at 37 1C. For western blot analysis, cells were reseeded in six-well plates at a density of 0.5 Â 10 6 cells/ml with fresh complete culture medium.
Western blot
Aliquots of 30 mg of protein from each sample were separated by 10% SDS-polyacrylamide gel electrophoresis and transferred onto a polyvinylidene difluoride membrane (Millipore, Bedford, MA, USA). After blocking with 10% instant nonfat dry milk for 1 h, membranes were incubated with specific antibodies overnight at 4 1C followed by incubation with secondary antibodies (HRP-conjugated anti-rabbit or antimouse IgG at the appropriate dilutions) for 45 min to 1 h at room temperature. Antibody binding was detected with the enhanced chemiluminescence detection system (Amersham Biosciences, Piscataway, NJ, USA).
Cell viability assay (MTT dye assay)
Cell viability was measured by the MTT method. Briefly, cells were collected and seeded in 96-well plates at a density of 5 Â 10 5 cells/cm 2 . Different seeding densities were optimized at the beginning of the experiments. 20 ml of MTT tetrazolium salt (Sigma) dissolved in Hank's balanced solution at a concentration of 5 mg/ml was added to each well with indicated treatment and incubated in CO 2 incubator for 4 h. Finally, the medium was aspirated from each well and 150 ml of DMSO (Sigma) was added to dissolve formazan crystals and the absorbance of each well was obtained using a Dynatech MR5000 plate reader at a test wavelength of 490 nm with a reference wavelength of 630 nm.
Assessment of the percentage of apoptotic cells
To detect apoptotic cells, cells were stained with DNA binding dye Hoechst 33342 as well as cytoplasm dye calcein. Cells with indicated treatment were fixed with 4% formaldehyde in phosphate buffered saline (PBS) for 10 min at 4 1C, and then washed with PBS. Cells were incubated for 20 min with 5 mg/ml of Hoechst 33342 (Sigma) to stain the nuclei and incubated with 2 mg/ml of Calcein (CalbioChem) to stain the cytoplasm. After washing with PBS, the apoptotic cells were observed under a Confocal Fluorescence microscope (Leica TCS SMD FCS, Leica, Germany). Cells exhibiting condensed chromatin and fragmented nuclei (Hoechst 33342 stain, Blue) as well as condensed cytoplasm (Calcein stain, Red) were scored as apoptotic cells. For each Hoechst/Calcein experiment, at least 200 cells in 5 random scope fields were counted for apoptotic rate.
Quantification of apoptosis by enzyme linked immunosorbent assay
The cell apoptosis enzyme linked immunosorbent assay Detection Kit (Roche, Palo Alto, CA, USA) was used to detect apoptosis in cancer cells after different treatments according to manufacturer's protocol. Briefly, after indicated treatments, the cytoplasmic histone/DNA fragments from cells were extracted and bound to immobilized anti-histone antibody. Subsequently, the peroxidase-conjugated anti-DNA antibody was used for the detection of immobilized histone/ DNA fragments. After addition of substrate for peroxidase, the spectrophotometric absorbance of the samples was determined by using Dynatech MR5000 plate reader at 405 nM.
TUNEL assay
The In Situ Cell Death Detection Fluorescein Kit, (Roche) was used to detect apoptosis in different cancer cells after indicated treatments according to manufacturer 0 s protocol. After treatment, the DNA fragments from the cells with different treatments were stained by TUNEL fluorescein, TUNELpositive stained cells were detected using a confocal fluorescence microscope (Leica TCS SMD FCS).
Confocal immunofluorescence
Cancer cells with indicated treatment were fixed in pre-cold (À20 1C) ethanol (70%) for 10 min at 4 1C. Fixed cells were blocked with 10% bovine serum albumin in PBS for 30 min at room temperature and then incubated with 1:100 rabbit anti-p-S6 (Ser235/236) for 1 h, followed by FITC-anti-rabbit secondary antibody (Cell Signaling Technology) at 1:100 for 30 min and p-S6 immunofluorescence was observed in a confocal microscopy (Leica TCS SMD FCS), Hoechst 33342 was used to stain the nuclear.
AMPKa RNA interference experiments siRNA for AMPKa1/a2 (sc-45312) was purchased from Santa Cruz Biotechnology. Cancer cells were cultured in a complete medium that did not contain antibiotics for 4 days. Cells were seeded in a 6-well plate 1 day prior to transfection and cultured to 50-60% confluence the following day. For RNA interference experiments, 6.25 ml of Lipofectamine LTX and 2.5 ml PLUS TM Reagent (Invitrogen) were diluted in 90 ml of DMEM for 5 min in room temperature. Then, 10 ml AMPKa siRNA (20 mM) was mixed with DMEM containing Lipofectamine together with PLUS reagent and incubated for 30 min at room temperature for complex formation. Finally, the complex was added to the wells containing 2 ml of medium with the final AMPKa siRNA concentration of 100 nM. AMPKa protein expression was determined by western blot 48 h after transfection.
ROS detection
Cancer cells were pre-loaded with 1 mM of fluorescent dye dihydrorhodamine (Invitrogen) 2 h before the indicated treatments, which reacts with ROS in cells and results in a change of fluorescence. After being treated with indicated treatments, cancer cells were trypsinized, suspended in ice-cold PBS and fixed in 70% ethyl alcohol in À20 1C. The changes in fluorescence in drug-treated cells were quantified by fluorescence-activated cell sorter analysis. Induction of ROS generation was expressed in arbitrary units.
Statistical analysis
The values in the figures are expressed as the means ± s.d.. The figures in this study were representatives of more than three different experiments. Statistical analysis of the data between the control and treated groups was performed by a Student's t-test. Values of Po0.05 were considered as statistically significant.
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